Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1954 2
1955 1
1956 2
1958 2
1959 1
1960 1
1961 2
1962 1
1963 1
1964 4
1965 4
1966 4
1968 3
1969 1
1970 2
1971 4
1972 4
1973 5
1974 2
1975 4
1976 1
1978 1
1982 3
1983 2
1984 3
1985 1
1986 2
1987 1
1988 3
1990 3
1991 2
1992 6
1993 3
1994 6
1995 6
1996 1
1997 5
1998 2
1999 5
2000 7
2001 6
2002 5
2003 4
2004 8
2005 4
2006 8
2007 5
2008 4
2009 5
2010 8
2011 6
2012 16
2013 14
2014 11
2015 11
2016 19
2017 12
2018 14
2019 15
2020 14
2021 10
2022 6
2023 11
2024 9
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Dombi E, et al. Among authors: ratner n. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. N Engl J Med. 2016. PMID: 28029918 Free PMC article. Clinical Trial.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, Allen JC, Schorry E, Korf B, Robison NJ, Goldman S, Vinks AA, Emoto C, Fukuda T, Robinson CT, Cutter G, Edwards L, Dombi E, Ratner N, Packer R, Fisher MJ. Weiss BD, et al. Among authors: ratner n. J Clin Oncol. 2021 Mar 1;39(7):797-806. doi: 10.1200/JCO.20.02220. Epub 2021 Jan 28. J Clin Oncol. 2021. PMID: 33507822 Free PMC article. Clinical Trial.
Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1.
Lucas CG, Gross AM, Romo CG, Dehner CA, Lazar AJ, Miettinen M, Pekmezci M, Quezado M, Rodriguez FJ, Stemmer-Rachamimov A, Viskochil D, Perry A; Symposium on Atypical Neurofibroma: State of the Science Members. Lucas CG, et al. Neuro Oncol. 2025 Mar 7;27(3):616-624. doi: 10.1093/neuonc/noae235. Neuro Oncol. 2025. PMID: 39500722 Free PMC article.
Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.
González-Muñoz T, Di Giannatale A, García-Silva S, Santos V, Sánchez-Redondo S, Savini C, Graña-Castro O, Blanco-Aparicio C, Fischer S, De Wever O, Creus-Bachiller E, Ortega-Bertran S, Pisapia DJ, Rodríguez-Peralto JL, Fernández-Rodríguez J, Pérez-Portabella CR, Alaggio R, Benassi MS, Pazzaglia L, Scotlandi K, Ratner N, Yohay K, Theuer CP, Peinado H. González-Muñoz T, et al. Among authors: ratner n. Clin Cancer Res. 2023 Sep 15;29(18):3744-3758. doi: 10.1158/1078-0432.CCR-22-2462. Clin Cancer Res. 2023. PMID: 37432984
Neurofibromatosis type 1: modeling CNS dysfunction.
Gutmann DH, Parada LF, Silva AJ, Ratner N. Gutmann DH, et al. Among authors: ratner n. J Neurosci. 2012 Oct 10;32(41):14087-93. doi: 10.1523/JNEUROSCI.3242-12.2012. J Neurosci. 2012. PMID: 23055477 Free PMC article. Review.
320 results